Revolution Medicines Stock Soars After Promising Cancer Drug Data
Revolution Medicines (NASDAQ: RVMD) shares surged 42% in early trading Monday after the biotech company released breakthrough clinical trial results for its experimental cancer drug. The stock hit a record high of $38.75 following the announcement, marking its biggest single-day gain since going public in 2020.
The Redwood City-based company reported that its lead drug candidate, RMC-6236, showed "unprecedented" tumor shrinkage rates in patients with advanced solid tumors. The Phase 1 trial data, presented Sunday at the American Association for Cancer Research conference, included responses in hard-to-treat KRAS-mutated cancers.
Wall Street analysts quickly upgraded their price targets, with JPMorgan raising its projection to $45 from $28. "These results could redefine treatment for KRAS-driven cancers," said lead investigator Dr. David Hong of MD Anderson Cancer Center. Approximately 25% of all human cancers involve KRAS mutations.
The surge comes amid heightened investor interest in oncology treatments, with the NASDAQ Biotechnology Index up 11% year-to-date. Revolution Medicines now boasts a market capitalization exceeding $3.5 billion, though the company has yet to generate commercial revenue.
Retail investors flooded social media platforms, with Revolution Medicines becoming a top-trending ticker on StockTwits. The company plans to begin Phase 2 trials this quarter while exploring accelerated FDA approval pathways. Competitors including Amgen and Mirati Therapeutics saw modest declines in their shares following the news.
Healthcare sector analysts note this development could trigger renewed M&A interest in the precision oncology space. Revolution Medicines previously partnered with Sanofi in a $5 billion deal for another drug candidate, though that agreement was terminated last year.
The stock's volatility reflects both the promise of the clinical data and the inherent risks of pre-revenue biotech investing. Revolution Medicines burned through $98 million last quarter and will likely need additional funding to advance its pipeline. Company executives declined to comment on potential fundraising plans during Monday's investor call.
